Parents Seek Experimental Therapy for Toddler's Fatal Muscular Dystrophy

The parents of a two-year-old boy diagnosed with Duchenne muscular dystrophy (DMD), a fatal genetic condition, are seeking an experimental therapy estimated to cost over £2 million. Wilf Barker was diagnosed with DMD earlier this year, a progressive muscle-wasting disease that currently has no cure. According to the NHS, most individuals with DMD live into adulthood but often succumb to heart or respiratory failure in their thirties.

Treatments that aim to correct the genetic mutation causing DMD are being developed and tested in the United States. Wilf's parents, Steve and Amy Barker, both 41, have launched a fundraiser to afford this potential therapy, stating their desperation to act for their son. "We’re desperate to do anything for our son, we couldn’t just sit here and do nothing," Steve Barker said.

The first indicators of Wilf's condition were noted when he showed a slight delay in sitting up, crawling, and walking. By 18 months old, he had not yet begun to walk, whereas the average age for children to start walking is 14 months. While doctors advised against comparing children, Amy Barker mentioned they considered if Wilf's delay was due to his personality. The family took Wilf to the GP in June 2025, leading to a referral to a pediatrician. However, Wilf began walking at 21 months old, while the family was on the waiting list for the specialist appointment. A subsequent appointment at the end of the year led to the parents being reassured that it was likely just a developmental delay, possibly related to flat feet and flexible ankles.

Further investigation began in September 2025 when Amy Barker experienced a miscarriage at eight weeks. Testing of the pregnancy tissue revealed a genetic variant linked to DMD. Subsequent testing in January confirmed Amy was a carrier for the condition. This discovery raised concerns for the parents, as they recognized potential symptoms in Wilf. "Once we did some research, it raised a lot of alarm bells for us because there were a lot of symptoms we thought Wilf had," Amy stated.

By January 2026, Wilf underwent blood tests, including a full genetic analysis, after Amy mentioned her carrier status at their final pediatrician appointment. The results confirmed Wilf's diagnosis of DMD in February, a revelation the parents described as their world "falling apart."

Specialists at Great Ormond Street Hospital later informed the family about the progressive nature of the disease. They explained that Wilf would continue to develop but at a slower pace than his peers until around age five or six, after which a decline would begin. Doctors anticipate he may start taking steroids around age four to slow the disease's progression and could require a wheelchair by age 12. Wilf is currently monitored every six months, with the frequency expected to increase over time.

DMD is an X-linked genetic disorder causing progressive muscle weakness, primarily affecting boys. It results from a deficiency in the dystrophin protein, leading to muscle fiber breakdown and replacement by fibrous or fatty tissue. This gradual deterioration affects muscles throughout the body. It is the most common form of muscular dystrophy in children, affecting approximately 1 in 3,500 to 5,000 live births.

While Wilf is currently active and enjoying life, his parents are trying not to dwell excessively on the future. The family is documenting their journey on Instagram to raise awareness about the disease. According to the NHS, individuals with DMD may require breathing assistance, feeding tubes, and can experience complications such as bladder and bowel issues, scoliosis, and dilated cardiomyopathy, a condition affecting the heart muscle.